![Wendy E. Rieder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wendy E. Rieder
Plus aucun poste en cours
Profil
Wendy E.
Rieder was the founder of Microbiotix, Inc. founded in 1998, where she held the title of COO & Vice President-Business Development in 2002.
She also held former positions as VP-Intellectual Property & Legal Affairs at Synta Pharmaceuticals Corp.
from 2002 to 2013, VP-Business Development & Intellectual Property at LipoGenics, Inc. from 1997 to 1999, Patent Agent at Fish & Neave LLP from 1991 to 1995, and Patent Attorney at Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997.
Ms. Rieder's education history includes a graduate degree from The Trustees of Columbia University in The City of New York and a graduate degree from Fordham University School of Law.
Anciens postes connus de Wendy E. Rieder
| Sociétés | Poste | Fin |
|---|---|---|
Microbiotix, Inc.
 Microbiotix, Inc. Pharmaceuticals: MajorHealth Technology Microbiotix, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing proprietary small molecule drugs to treat serious infectious diseases, including multi-drug resistant pathogens. The company is based in Worcester, MA. The company's lead candidate, MBX-400 (filociclovir), is a novel nucleoside analog with a dual DNA polymerase/kinase inhibitory mechanism targeting human cytomegalovirus infections and has completed phase 1 clinical trials. The company’s pipeline includes antibiotics such as spectinamides and aminospectinomycins aimed at drug-resistant tuberculosis, drug-resistant Neisseria gonorrhoeae, and other priority pathogens. Additional programs target bacterial virulence factors, trans-translation pathways, and efflux pumps to combat resistance in gram-negative bacteria. The company was founded by Wendy E. Rieder. | Fondateur | 01/12/2002 |
LipoGenics, Inc.
 LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Manufactures dietary supplements | Corporate Officer/Principal | 01/12/1999 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Corporate Officer/Principal | 01/07/1997 |
Fish & Neave LLP
 Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services specializing in intellectual property | Corporate Officer/Principal | 01/07/1995 |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs | Corporate Officer/Principal | - |
Formation de Wendy E. Rieder
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
8
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Health Technology |
LipoGenics, Inc.
LipoGenics, Inc. Food: Meat/Fish/DairyConsumer Non-Durables Manufactures dietary supplements | Consumer Non-Durables |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fish & Neave LLP
Fish & Neave LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services specializing in intellectual property | Commercial Services |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Microbiotix, Inc.
Microbiotix, Inc. Pharmaceuticals: MajorHealth Technology Microbiotix, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing proprietary small molecule drugs to treat serious infectious diseases, including multi-drug resistant pathogens. The company is based in Worcester, MA. The company's lead candidate, MBX-400 (filociclovir), is a novel nucleoside analog with a dual DNA polymerase/kinase inhibitory mechanism targeting human cytomegalovirus infections and has completed phase 1 clinical trials. The company’s pipeline includes antibiotics such as spectinamides and aminospectinomycins aimed at drug-resistant tuberculosis, drug-resistant Neisseria gonorrhoeae, and other priority pathogens. Additional programs target bacterial virulence factors, trans-translation pathways, and efflux pumps to combat resistance in gram-negative bacteria. The company was founded by Wendy E. Rieder. | Health Technology |
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs | Health Technology |
Fordham University School of Law
 Fordham University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
